What are the realities and dilemmas behind the departure of 18 pharmaceutical company chairman in 2020?

2020 is an extraordinary year for the pharmaceutical industry, with innovative pharmaceutical companies financing, pipeline prosperity and gradual listing, multinational pharmaceutical companies continuing to divest non-core assets, reconstructing business and organizational frameworks, and traditional pharmaceutical companies seeking new vitality under the dual pressure of policy and performance.
such an industry change, the pharmaceutical industry in 2020 ushered in a number of personnel changes and restructuring.
according to E drug managers incomplete statistics, which, involving the chairman of the adjustment reached 18 as many, all kinds of behind the fate of various enterprises and people.
01 Hengrui Medicine: Sun Weiyang stepped down in January 2020, "Pharma one brother" Hengrui at the helm of Sun Weiyang stepped down as chairman.
as the largest pharmaceutical company in China, Hengrui has been attracting attention.
, born in 1958, has been in charge of Hengrui Pharmaceuticals for 30 years since the 1990s.
his leadership, Hengrui Pharmaceuticals has developed from a small pharmaceutical factory in northern Subei to a leader in China's pharmaceutical industry.
in the eyes of the outside world, Sun is a low-key, rarely in the media public appearances.
has long been highly regarded by the outside world for his emphasis on pharmaceutical research and development, especially in the company's financial statements, the company every year to carry out research and development.
he stepped down at the beginning of the year, Hengrui's market capitalisation had reached about $400 billion.
step down from his position as chairman this time, Mr Sun did not "let go" entirely, but continued to serve as a director and chairman of the Strategic Development Committee.
addition, Sun also set up a joint venture with Hengrui Pharmaceuticals to focus on antiviral drugs of the new company.
the post of chairman of the board of directors is general manager Zhou Yunshu.
Is similar to most of Hengrui Pharmaceutical's executives, Zhou Yunshu is Hengrui's "old man", who joined Hengrui in 1995 after graduating from the Chinese Pharmaceutical University, and has been an internal executive of Hengrui, responsible for many aspects of the business.
has been the general manager of Hengrui Pharmaceuticals since 2003, and Zhou Yunshu has been in this position for 17 years.
note that in mid-2020, Jiang Xinhua, Sun Hui, Liu Xinjiang and Li Kejian, vice-presidents of Hengrui Pharmaceuticals, also submitted resignation reports, and they applied to resign as vice-presidents of the company because of their age.
these executives have also d'Anrui Pharmaceuticals for more than 15 years, which Hengrui Pharmaceuticals calls the normal executive team metabolism.
02 Fosun Pharma: At the end of October 2020, Chen Qiyu and Yao Fang resigned as Chairman and Co-Chairman of Fosun Pharma, respectively, while Fosun Pharma announced that Wu Yifang had taken over as Chairman and served as Executive Director and CHIEF Executive Officer.
Wu was previously president and CEO of Fosun Pharma.
Same day, Fosun Pharma also announced new appointments for several co-presidents, chief financial officers and senior vice presidents, while Fosun Pharma made several executive changes in the first half of the year, and the head drug company did make a big change in the executive team in 2020.
the move at the highest level, there have been movements.
in February, Wang Qunbin, who had been with the company's founder Guo Guangchang for 28 years, was promoted to co-chairman and will no longer serve as CEO, while Chen Qiyu, the former co-president of the company, and Xu Xiaoliang were promoted to co-CEO.
this move marks Chen Qiyu and Xu Xiaoliang taking over the day-to-day operation and management of Fosun International, a global company.
Wang Qunbin will take time out from the company's day-to-day management and work with Guo Guangchang to devote more energy to top-level design, strategy development and team development.
, the change is a step in Chen Qiyu's move away from Fosun Pharma and into Fosun International Management.
For Fosun Pharma, in the past 10 years, under the development model of "endoentic growth, extended expansion and integrated development", it has become a company focused on the main pharmaceutical industry, diversified business portfolio development, its pharmaceutical research and development, device diagnostics and medical services business sectors are growing steadily, but also the birth of Fuhong Hanxuan, Fosun Kate, Fusun Pharmaceuticals and other star companies.
's change of management also marks a new phase for the innovative and internationally represented company, which will leave Mr Wu with the task of bringing Fosun Pharma to a faster track and a higher position.
03 Kangmei Pharmaceuticals: Tree Falling Scatter is different from Sun's "retirement", Chen Qiyu ascended to Fosun International level, the past also known as the "white horse stock" of Kangmei Pharmaceuticals Ma Xingtian is a different picture.
the 20th anniversary of the founding of Comey Pharmaceuticals in 2017, its revenue has reached 26.4 billion yuan, the company's market value has already exceeded 100 billion yuan, is a typical blue-chip white horse stock.
by virtue of Kangmei Pharmaceuticals' 100 billion market value, the company's chairman Ma Xingtian became a frequent visitor to various rich lists.
, behind the miraculous growth of Comey's pharmaceutical industry, there is a lot of fraud and rye.
2018, Comey Pharmaceuticals has been repeatedly questioned about financial fraud, and in December 2018, Comey Pharmaceuticals was investigated by the Securities and Futures Commission for alleged information disclosure violations.
April 2019, Comey Pharmaceuticals suddenly "self-exposed" accounting errors in financial data, a nearly $30 billion financial fraud surfaced.
this has raised strong questions and shocked the entire capital market.
a leading pharmaceutical industry company even financial fraud, "Big White Horse" overnight became a "black swan."
Ma Xingtian was clearly prepared to move the most worthy assets to his children in advance.
until July 9, 2020, Kangmei Pharmaceuticals announced that it had received notice from the family of Ma Xingtian, the company's actual controller, that Ma Xingtian had been coerced by the public security authorities for allegedly disclosing and not disclosing important information in violation of the law.
before Ma Xingtian was arrested, he had applied to resign as chairman and general manager of the company, with Ma Xinggu taking over as chairman of the company.
Xu Dongxuan also resigned as vice chairman and executive vice president of the company.
a large number of other executives have also resigned.
2020 pharmaceutical company chairman adjustment list: 04 to promote mixed reform, work adjustment, shell listing ... Wei Navy, chairman of Northeast Pharmaceuticals, announced his resignation in early October 2020 and has been at the helm of the group for more than seven years.
2013, Wei was transferred from shenyang municipal government to Northeast Pharmaceuticals as chairman, and during his seven years at the helm of Northeast Pharmaceuticals, he pushed through a series of reforms at the old state-owned company.
to accelerate the development of biopharmaceutical and pharmaceutical projects, introduce competitive induction mechanisms, recruit professional managers directly from outside, and form a diversified equity allocation organization with state-owned, private, social capital and employee ownership.
2018, Liaoning Fangda Group became the controlling shareholder of Northeast Pharmaceuticals by increasing its holdings, after the state-owned Northeast Pharmaceutical Group had been the largest shareholder of Northeast Pharmaceuticals.
To complete the offer to buy The Fangda Group real controller Fang Wei to the Northeast Pharmaceutical research made it clear that the Group will be in all aspects of policy, financial support, the future of Northeast Pharmaceuticals to the standard Hengrui Pharmaceutical, which is also the next chairman of Northeast Pharmaceuticals need to consider the issue.
Shortly thereafter, North China Pharmaceuticals also announced that Yang Guo occupied the board of directors to apply to resign as a director and chairman of the company, and also resigned as chairman of the company's board of directors strategy (investment decision-making) committee and nomination and compensation appraisal committee.
resignation, Yang Guo occupied no longer held any position in the company.
the reasons given by the company for this change are the reasons for the work.
In 2020, Wang Xuehai, chairman of People's Fu Pharmaceuticals, also submitted a resignation report, announcing that Wang Xuehai had offered to resign as chairman of People's Fu Pharmaceuticals due to the adjustment of the division of labor, while Wang Xuehai continued to serve as director of People's Fu Pharmaceuticals, and his position in the subsidiary of the company remained unchanged.
, president of Fufu Pharmaceuticals, was elected chairman.
And Wang Xuehai used to be famous for daring to say, as early as 2014, in an interview with the media, Wang Xuehai said that the company intends to acquire 20 hospitals, and then the company's director came forward to clarify, and then Wang Xuehai has thrown out the "proposed construction of 50 hospitals", "apply for two funds", "split the business sector listing" and other statements, the company's director had to come forward again and again to clarify, called it "the chairman's personal development vision" does not constitute an investment commitment.
the resignation of the same executives, unlike previous resignations for personal reasons, the company's strategic adjustment, as well as the adjustment of work arrangements, is becoming the main reason for the resignation of senior executives.
most obvious one is Huatong Pharmaceuticals.
the evening of October 8, 2020, Huatong Pharmaceuticals announced that its chairman, Wang Luping, and some directors and supervisors had submitted written resignation reports.
and behind this is a shell listing.
Huatong Pharmaceuticals entered the A-share market in May 2015, mainly engaged in wholesale pharmaceutical, chain retail.
recent years, Huatong Pharmaceutical's operating performance is not very ideal.
2020, Huatong Pharmaceutical's major asset restructuring was approved by the CSRC.
reorganization plan shows that Huatong Pharmaceutical's restructuring target is Zhejiang Agricultural Group Co., Ltd. (referred to as Zhejiang Agricultural Shares) 100% equity, Zhejiang Agricultural Shares to agricultural integrated services and automotive business services for the dual main business operation, its profitability is stable.
industry said that the completion of the restructuring, financing channels to broaden, will be conducive to ease the pressure on funds, the two companies thus entered a benign development track.
January 8, Huatong Pharmaceuticals (002758) Securities was officially changed to Zhejiang Nong shares, and Wang Luping is the chairman of Zhejiang Agricultural Holdings.
And in 2020, the chairman of the pharmaceutical company also has Sun Jilin (personal reasons), Shapu Ace's Chen Dekang (personal reasons), Tianrui Pharmaceuticals Zhong Ming (personal reasons), Longxiang Pharmaceuticals' Hu Wenqiang (personal reasons), Jiangsu Wuzhong Zhao unique (age reason), Rui Yi Technology's Guo Qing (work arrangement), Ji Pharmaceutical Holdings' Sun Jun (perfect corporate governance), Haichang Pharmaceutical's Zeng Chunhui (business management needs), Pro Pharmaceuticals' Zhu Fang mammoth (job needs), Lisheng Pharmaceuticals' Qi tie bolt (work changes) and so on.
Looking at the changes in executives in 2020, we can see that some enterprises have more frequent changes in personnel, and even the phenomenon of collective resignation of senior executives;
And in the future, with the normalization of collection, pharmaceutical companies to maintain market share, reduce sales costs and change the past pharmaceutical representative marketing model is a necessary path, in the process, the need to update the more responsive pharmaceutical management thinking, the original set of thinking is no longer suitable for today's Chinese pharmaceutical industry.
not surprising that pharmaceutical companies are adjusting more frequently under the dual considerations of policy change and performance pressure, and that this large-scale adjustment is unlikely to diminish in 2021.
。